Surveillance nosokomialer Infektionen in der pädiatrischen Hämatologie/Onkologie

Abstract

Immunocompromised patients in pediatric hematology-oncology are faced with an increased risk of nosocomial infections (NI). The incidence of NI and the contribution of certain risk factors have not sufficiently been investigated in this population. It is therefore unknown how many NI are preventable through infection control measures. The surveillance of NI in pediatric hematology-oncology departments should focus on device-associated infections (central venous catheter infection, urinary tract infection), on nosocomial pneumonia (in particular due to Aspergillus) and on infectious complications caused by Respiratory Syncytial-Virus and Rotavirus. The surveillance protocol should be based on a modified version of the Centers for Disease Control and Prevention methods (established definitions of NI can not be completely applied to pediatric oncology patients). Prospective surveillance for NI on pediatric hematology/oncology units is an indispensable tool for internal quality control. The careful evaluation of specific NI-rates permits the identification of critical control points, that may be targeted by infection control programs.

Impact of a modified Broviac maintenance care bundle on bloodstream infections in paediatric cancer patients

“…The prospective Oncoped tool for the surveillance of healthcare-related infections in paediatric cancer patients in Germany has been previously described in detail [ 5 ], [ 6 ], [ 12 ], [ 25 ]. Incidence densities (ID; BSI per 100 inpatient days) and incidence rates (IR; BSI per 1,000 CVAD utilization days) were calculated.…”

Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute

“…For severely immunosuppressed patients, however, surveillance includes other BSI (see definition B3 in ONKO-KISS [haemato-oncology component of the nosocomial infection surveillance system]).) as set out in the German Infection Protection Act (Infektionschutzgesetz, IfSG) [ 323 ] and corresponding comments by the RKI [ 324 ], [ 325 ], [ 326 ], [ 327 ], [ 328 ], [ 329 ], [ 330 ] (cat. IB).…”